Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Cohen

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Oncologist|October 27, 2007
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphomaBhupinder S Mann, John R Johnson, Martin H Cohen, et al.
The Oncologist|August 5, 2005
FDA drug approval summary: erlotinib (Tarceva) tabletsMartin H Cohen, John R Johnson, Yeh-Fong Chen, et al.
The Oncologist|May 25, 2007
FDA drug approval summary: panitumumab (Vectibix)Ruthann M Giusti, Kaushikkumar A Shastri, Martin H Cohen, et al.
The Oncologist|June 22, 2005
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancerMartin H Cohen, John R Johnson, Yong-Cheng Wang, et al.
The Oncologist|September 12, 2008
FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuriaAndrew Dmytrijuk, Kathy Robie-Suh, Martin H Cohen, et al.
The Oncologist|February 3, 2004
FDA drug approval summaries: oxaliplatinAmna Ibrahim, Steven Hirschfeld, Martin H Cohen, et al.
The Oncologist|December 15, 2010
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)Martin H Cohen, John R Johnson, Somesh Chattopadhyay, et al.
The Oncologist|October 14, 2008
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2Qin Ryan, Amna Ibrahim, Martin H Cohen, et al.
The Oncologist|April 12, 2013
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancerMartin H Cohen, Huanyu Chen, Stacy Shord, et al.
The Oncologist|September 25, 2012
U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanomaThomas M Herndon, Suzanne G Demko, Xiaoping Jiang, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Oncologist|October 27, 2007
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphomaBhupinder S Mann, John R Johnson, Martin H Cohen, et al.
The Oncologist|August 5, 2005
FDA drug approval summary: erlotinib (Tarceva) tabletsMartin H Cohen, John R Johnson, Yeh-Fong Chen, et al.
The Oncologist|May 25, 2007
FDA drug approval summary: panitumumab (Vectibix)Ruthann M Giusti, Kaushikkumar A Shastri, Martin H Cohen, et al.
The Oncologist|June 22, 2005
FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancerMartin H Cohen, John R Johnson, Yong-Cheng Wang, et al.
The Oncologist|September 12, 2008
FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuriaAndrew Dmytrijuk, Kathy Robie-Suh, Martin H Cohen, et al.
The Oncologist|February 3, 2004
FDA drug approval summaries: oxaliplatinAmna Ibrahim, Steven Hirschfeld, Martin H Cohen, et al.
The Oncologist|December 15, 2010
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)Martin H Cohen, John R Johnson, Somesh Chattopadhyay, et al.
The Oncologist|October 14, 2008
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2Qin Ryan, Amna Ibrahim, Martin H Cohen, et al.
The Oncologist|April 12, 2013
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancerMartin H Cohen, Huanyu Chen, Stacy Shord, et al.
The Oncologist|September 25, 2012
U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanomaThomas M Herndon, Suzanne G Demko, Xiaoping Jiang, et al.
Pageof 4